Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic

Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in On...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblat, Joshua D., Lipsitz, Orly, Di Vincenzo, Joshua D., Rodrigues, Nelson B., Kratiuk, Kevin, Subramaniapillai, Mehala, Lee, Yena, Arekapudi, Anil K., Abrishami, Amir, Chau, Edmond H., Szpejda, Witold, Wong, Leslie, Mansur, Rodrigo B., McIntyre, Roger S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240444/
https://www.ncbi.nlm.nih.gov/pubmed/34246008
http://dx.doi.org/10.1016/j.psychres.2021.114086
Descripción
Sumario:Herein we evaluate the impact of COVID-19 restrictions on antidepressant effectiveness of intravenous (IV) ketamine in adults with treatment-resistant depression (TRD). We conducted a case series analysis of adults with TRD (n = 267) who received four ketamine infusions at an outpatient clinic in Ontario, Canada, during COVID-19 restrictions (from March 2020 - February 2021; n = 107), compared to patients who received treatment in the previous year (March 2019 - February 2020; n = 160). Both groups experienced significant and comparable improvements in depressive symptoms, suicidal ideation, and anxiety with repeated ketamine infusions. Effectiveness of IV ketamine was not attenuated during the COVID-19 period.

Ejemplares similares